CLINICAL TRIALS PROFILE FOR PANHEMATIN
✉ Email this page to a colleague
All Clinical Trials for PANHEMATIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00467610 ↗ | Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS | Terminated | H. Lundbeck A/S | Phase 2 | 2007-05-01 | This is a Phase II, open-label clinical trial examining the role of Panhematin® in patients with MDS. The objective of this study is to evaluate the safety and efficacy of Panhematin® (hematin for injection) in the treatment of adult patients (≥ 18 years of age) with low-risk MDS. The study will be conducted on an outpatient basis and will consist of the following: - A Screening Period (within 28 days of the Day 1) - Screening bone marrow aspiration and biopsy up to 60 days prior to receiving study medication - An 8-week Treatment Period (Days 1 through 4 of Week 1, and weekly visits during Weeks 2 through 8); partial and complete responders in any of the three cell lines may continue treatment for an additional 4 weeks - A 6-month Post treatment Follow-up Period (monthly clinic visits during Weeks 12 40) |
| NCT00467610 ↗ | Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS | Terminated | Rush University Medical Center | Phase 2 | 2007-05-01 | This is a Phase II, open-label clinical trial examining the role of Panhematin® in patients with MDS. The objective of this study is to evaluate the safety and efficacy of Panhematin® (hematin for injection) in the treatment of adult patients (≥ 18 years of age) with low-risk MDS. The study will be conducted on an outpatient basis and will consist of the following: - A Screening Period (within 28 days of the Day 1) - Screening bone marrow aspiration and biopsy up to 60 days prior to receiving study medication - An 8-week Treatment Period (Days 1 through 4 of Week 1, and weekly visits during Weeks 2 through 8); partial and complete responders in any of the three cell lines may continue treatment for an additional 4 weeks - A 6-month Post treatment Follow-up Period (monthly clinic visits during Weeks 12 40) |
| NCT00882804 ↗ | Hemin in Healthy Subjects | Completed | Mayo Clinic | Phase 1 | 2009-02-01 | This study is being done because we want to learn if hemin can increase the production of heme oxygenase 1. Heme oxygenase 1 (HO-1) is an enzyme which protects cells from physical, chemical, and biologic stress. Hemin is produced from red blood cells and is approved by the Food and Drug Administration for treating acute porphyria, which is an inherited condition caused by an enzyme deficiency. |
| NCT02935400 ↗ | Acute Porphyria Biomarkers for Disease Activity | Active, not recruiting | The University of Texas Medical Branch, Galveston | 2014-04-28 | The long term objective of the research is to identify new biomarkers of disease activity in the human acute porphyrias. This pilot study is intended to provide pilot and feasibility data needed to plan larger and more definitive future studies. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PANHEMATIN
Condition Name
Clinical Trial Locations for PANHEMATIN
Trials by Country
Clinical Trial Progress for PANHEMATIN
Clinical Trial Phase
Clinical Trial Sponsors for PANHEMATIN
Sponsor Name
